CNO Financial Gr (NYSE:CNO) reported quarterly earnings of $0.49 per share which met the analyst consensus estimate. This is a 31.94 percent decrease over earnings of $0.72 per share from the same period last year. The company reported quarterly sales of $905.30 million which beat the analyst consensus estimate of $893.79 million by 1.29 percent. This is a 6.51 percent decrease over sales of $968.30 million the same period last year.
Cantex and Miami Cancer Institute Announce FDA Clearance for a Clinical Trial Investigating Azeliragon Combined with Stereotactic Radiosurgery for the Treatment of Brain Metastases
Cantex Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on developing transformative therapies for cancer and other life-threatening medical conditions, and Baptist Health Miami Cancer
